Sacituzumab tirumotecan improved progression-free and overall survival versus chemotherapy in previously treated endometrial cancer
In a randomized phase 3 trial, sacituzumab tirumotecan improved progression-free and overall survival versus physician’s-choice chemotherapy in previously treated endometrial...









